How to Help Your Patients Find Jatenzo in Stock: A Provider's Guide

When you prescribe Jatenzo (testosterone undecanoate) for a patient, writing the prescription is often the easiest part. What follows — navigating prior authorizations, pharmacy availability gaps, and cost barriers — can be far more challenging. And when patients can't fill their prescriptions, they call your office.

This guide is designed to help your practice proactively address the most common Jatenzo access obstacles — before the patient hits a wall. It covers pharmacy availability tools, savings program enrollment, prior auth documentation, and when to consider alternatives.

Step 1: Check Pharmacy Availability Before Sending the Prescription

One of the most effective things your practice can do is verify that a pharmacy can fill the prescription before you send it. medfinder for Providers allows your staff to check which pharmacies near your patient have Jatenzo in stock or can special-order it within 1–3 business days. This simple step prevents the most common frustration: a prescription sent to a pharmacy that can't fill it.

Independent pharmacies and specialty pharmacies are more likely to stock Jatenzo or be willing to order it than large chain pharmacies. If your patient is near a men's health specialty pharmacy or a hormonal therapy-focused pharmacy, direct them there first.

Step 2: Build a Strong Prior Authorization From Day One

Prior authorization is the most common barrier to Jatenzo access. A well-documented PA request significantly increases approval rates. Your PA letter should include:

Two separate morning serum testosterone values confirming hypogonadism (below 300 ng/dL or lab reference range)

Confirmed diagnosis of primary or hypogonadotropic hypogonadism with the underlying etiology documented (Klinefelter syndrome, pituitary pathology, chemotherapy-related, etc.)

Documentation of trial and failure of, or contraindication to, generic injectable testosterone AND generic topical testosterone gel

Clinical rationale for oral formulation (injection aversion, skin condition, skin transfer risk to children/partner, patient adherence concerns)

Prescribed dose within FDA-labeled range and evidence that the dose is being titrated based on lab monitoring

Remind your staff to flag PA expiration dates. Most PA approvals last 12 months. Start the renewal process 4–6 weeks before expiration to prevent coverage gaps.

Step 3: Enroll Patients in Savings Programs at the Point of Prescribing

Without savings assistance, Jatenzo costs $1,300–$1,700+ per month at retail. This is one of the most common reasons patients abandon their prescriptions at the pharmacy. Proactively connecting patients with Tolmar's savings programs at the point of prescribing — not after they've already hit a wall — dramatically improves prescription fill rates.

Key programs to communicate to patients:

Jatenzo Copay Card: For commercially insured patients, reduces monthly cost to $0 (up to $393 covered per fill, 12 fills/year). Apply at jatenzo.com.

Coverage-denied rate: Commercially insured patients whose PA is denied may pay $150/month at contracted pharmacies.

Cash patient program: Uninsured or cash-pay patients can purchase Jatenzo for $185/month through Tolmar's contracted pharmacy network.

Note: Government-insured patients (Medicare, Medicaid, TRICARE) are not eligible for the copay card.

Step 4: Handling Medicare Patients

Medicare Part D plans generally do not cover Jatenzo without a formulary exception. For Medicare patients, consider the following options:

Submit a formulary exception request with strong clinical justification, especially if the patient has documented failure or intolerance to covered formulations

Discuss alternative TRT formulations that are on the Medicare formulary (generic testosterone cypionate, generic testosterone gel) if the exception request is denied

Refer Medicare patients to patient advocacy organizations or NeedyMeds.org for additional assistance programs

Step 5: When to Recommend an Alternative Formulation

Despite best efforts, some patients will not be able to fill Jatenzo. Consider switching if:

All PA appeals are denied and the patient cannot afford $185/month

The patient has a formulary-covered formulation available that is clinically appropriate

The patient's testosterone is well-controlled and the switch is primarily cost-driven

If switching from Jatenzo to injections: do not attempt to directly dose-match. Restart with the standard starting dose of the injection formulation and titrate based on monitoring. Note that injectable testosterone cypionate remains in intermittent shortage; check availability before transitioning.

Monitoring Checklist for Jatenzo Patients

Serum testosterone: 6 hours post-morning dose, at least 7 days after initiation or dose change; periodically thereafter

Blood pressure: ~3 weeks after initiation or dose change; ongoing periodic monitoring

Hematocrit: every 3 months

PSA: at baseline and periodically during treatment

Lipids: monitor for changes in HDL and LDL

Blood glucose: in patients with diabetes, monitor more frequently as androgens may lower blood glucose

For a broader clinical briefing on the Jatenzo prescribing landscape in 2026, see our provider overview of Jatenzo access challenges.